Comparative Pharmacology
Head-to-head clinical analysis: KIMIDESS versus NORCEPT E 1 35 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KIMIDESS versus NORCEPT E 1 35 21.
KIMIDESS vs NORCEPT-E 1/35 21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KIMIDESS (ketoconazole) is an imidazole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the cytochrome P450 enzyme lanosterol 14-alpha-demethylase.
Combination oral contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin secretion, preventing ovulation; progestin (norethindrone) alters cervical mucus, endometrial lining, and inhibits sperm penetration.
5 mg orally once daily, with or without food.
One tablet (norethindrone 1 mg + ethinyl estradiol 35 mcg) orally once daily for 21 days, followed by 7 days of placebo or no tablets. Repeat cycle continuously.
None Documented
None Documented
Terminal elimination half-life is 14 hours (range 10-18 h); supports twice-daily dosing in most patients.
Ethinyl estradiol: terminal half-life approximately 17 hours (range 13-27 hours), consistent with once-daily dosing; norethindrone: terminal half-life approximately 7.6 hours (range 5-12 hours), permitting steady-state within 5 days.
Renal excretion of unchanged drug accounts for approximately 40% of the administered dose; biliary/fecal elimination accounts for 50%, with the remainder undergoing metabolic clearance.
Renal: 50-60% as metabolites (primarily ethinyl estradiol glucuronide and norethindrone metabolites); fecal: 20-30% via biliary elimination; unchanged drug: <5%.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive